6963-40-2Relevant academic research and scientific papers
Synthesis and antihypertensive activities of new 1,4-dihydropyridine derivatives containing a nitrooxy moiety at the 3-ester position
Ogawa,Nakato,Tsuchida,Hatayama
, p. 108 - 116 (2007/10/02)
The synthesis of a new series of dihydropyridines containing a nitrooxy moiety at the 3-ester position is described. The antihypertensive activity of the compounds was examined and compared with that of nifedipine; some of them were relatively potent. The structure-activity relationship is also discussed.
Studies on nilvadipine. II. Synthesis and structure-activity relationships of 2-hydroxymethyl- and 2-cyano-1,4-dihydropyridines containing heteroatom-substituted ester at the 5-position
Satoh,Ichihashi,Okumura
, p. 912 - 919 (2007/10/02)
The synthesis of new 2-hydroxymethyl- and 2-cyano-1,4-dihydropyridines possessing a heteroatom-substituted alkyl ester group at the 5-position of the nucleus is described. The esters were introduced via a suitable method selected from the modified Hantzsch method (method A), the hydrolysis of a chloroethyl ester obtained by method A (method B) or the replacement of the chlorine atom with various kinds of amino groups (method C). Hydroxymethyl and cyano groups at the 2-position were prepared in a similar manner to that described in a previous paper. The hypotensive activities of the compounds prepared in this paper were compared with the corresponding alkyl ester at the 5-position reported previously. It was found that N-benzylmethylaminoethyl esters, especially N-(4-chlorobenzyl)and N-(3,4-dichlorobenzyl)-N-methylaminoethyl esters, were suitable substituents at the 5-position of the 1,4-dihydropyridine nucleus and that these substituents were somewhat more effective for hypotensive activity than simple alkyl esters in a series of 2-hydroxymethyl-1,4-dihydropyridine derivatives. But it was found that the effect was reversed in a series of 2-cyano-1,4-dihydropyridine derivatives. Both of them were found to be inferior to nilvadipine (1c), accepted in clinical use for the treatment of hypertension.
